A recent clinical trial has revealed that a single dose of psilocybin, the active compound in magic mushrooms, could be an effective treatment for cocaine addiction. The study, published in JAMA Network Open, involved 36 participants, with 19 receiving psilocybin and 17 receiving a placebo of diphenhydramine, a common antihistamine. Those who took psilocybin were more likely to abstain from cocaine use.
Urgent Need for Treatment
Dr. Peter Hendricks, lead author and behavioral health professor at the University of Alabama at Birmingham, emphasized the urgency of finding effective treatments for cocaine use disorder. Currently, there are no FDA-approved medications for stimulant addictions like cocaine or methamphetamine. Overdoses involving stimulants are on the rise, and global cocaine production has reached record levels.
Hendricks initially sought to explore how psilocybin could help reduce incarceration rates. Data from Birmingham showed that cocaine use was the strongest predictor of criminal justice involvement and recidivism, particularly among low-income Black men. Although white individuals report higher lifetime cocaine use, Black individuals are disproportionately arrested for cocaine-related crimes.
Mechanism of Action
Experts suggest that psilocybin may work by increasing neuroplasticity and psychological flexibility, helping individuals break free from rigid, impulsive behaviors associated with addiction. Unlike traditional addiction medications that target the same neurochemical systems as the addictive substance, psilocybin induces a profound altered state of consciousness, typically in a single session within a structured therapeutic context.
Gabrielle Agin-Liebes, a clinical psychologist at Yale School of Medicine, explained that psilocybin acts as a catalyst for therapeutic change rather than a maintenance medication. It facilitates shifts in perspective and self-compassion, which can be particularly effective for cocaine addiction, as withdrawal symptoms are more psychological than physical.
Study Limitations and Potential
A critical commentary noted that the study excluded participants with comorbid depression and anxiety, which may limit generalizability. However, psilocybin has shown promise for these conditions as well. The study is notable for being the first psychedelic clinical trial with a majority of Black participants, addressing the lack of diversity in such research.
Recruitment for this trial did not explicitly mention psychedelics, reducing the expectation effect that can bias results. The researchers simply sought individuals trying to quit cocaine, resulting in a sample representative of the local population with cocaine use disorder.
Overall, the findings indicate that psilocybin-assisted therapy is a promising treatment for cocaine addiction, warranting larger-scale clinical trials.
